Welcome to
Èçäàòåëüñòâî Àòìîñôåðà

· Æóðíàëû
· Êíèãè
· Î ïðîåêòå

·Ýëåêòðîííûå âåðñèè êíèã èçäàòåëüñòâà “Àòìîñôåðà” ïîñòóïèëè â ïðîäàæó

Èçäàòåëüñòâî “Àòìîñôåðà” èäåò â íîãó ñî âðåìåíåì è îòêðûâàåò íà ñâîåì ñàéòå ðàçäåë ýëåêòðîííûõ âåðñèé ñâîèõ êíèã. Òåïåðü âû ìîæåòå ïðèîáðåñòè íå òîëüêî òðàäèöèîííóþ áóìàæíóþ êíèãó â êàðòîííîì ïåðåïëåòå, íî è .pdf-ôàéë, ñíàáæåííûé ãèïåðññûëêàìè íà êàæäóþ ãëàâó èçäàíèÿ.  ýëåêòðîííîé âåðñèè ïðîùå îòûñêàòü ðèñóíîê è òàáëèöó. ×òîáû îáðàòèòüñÿ ê íèì, äîñòàòî÷íî íàæàòü íà ññûëêó íà êàæäûé èç íèõ. Èñ÷åçëà çàâèñèìîñòü îò òèðàæà – âû ìîæåòå ïðèîáðåñòè äàæå òå áåñòñåëëåðû, òèðàæ êîòîðûõ óæå ðàçîøåëñÿ, òàêèå êàê “Ñàðêîèäîç” èëè “Çàáîëåâàíèÿ îðãàíîâ äûõàíèÿ ïðè áåðåìåííîñòè”. Óïðîñòèëîñü ïîëó÷åíèå âàìè êíèã – â òå÷åíèå äâóõ ðàáî÷èõ äíåé ïîñëå îïëàòû òðåáóåìûå ôàéëû ïðèäóò íà âàø e-mail. Íó è íàêîíåö, öåíà – ýëåêòðîííûå âåðñèè íàøèõ êíèã ãîðàçäî äåøåâëå, ÷åì áóìàæíûå èçäàíèÿ. Çàêàçûâàéòå ýëåêòðîííûå âåðñèè êíèã èçäàòåëüñòâà “Àòìîñôåðà” íà ñàéòå, à òàêæå ïî òåëåôîíó: (495) 730-63-51 è ïî e-mail: atm-press2012@yandex.ru



ÈÍÒÅÐÍÅÒ-ÌÀÃÀÇÈÍ
Èçäàòåëüñòâî Àòìîñôåðà


Òåëåôîí èçäàòåëüñòâà

  
Íåðâíûå áîëåçíè
2010 / N 1

Íåéðîïðîòåêòèâíûé ìåõàíèçì äåéñòâèÿ 1"(R)"àìèíîèíäàíà – îñíîâíîãî ìåòàáîëèòà ïðîòèâîïàðêèíñîíè÷åñêîãî ïðåïàðàòà ðàçàãèëèíà (Àçèëåêòà) (Ñïèñîê ëèòåðàòóðû)


Abu-Raya S., Blaugrund E., Trembovler V., Shilderman-Bloch E., Shohami E. and Lazarovici P. (1999) Rasagiline, a monoamine oxidase-B inhibitor, protects NGF-different PC12 cells against oxygen-glucose deprivation. J. Neurosci. Res. 58, 456–463.
   Abu-Raya S., Tabakman R., Blaugrund E., Trembovler V. and Lazaro- vici P. (2002) Neuroprotective and neurotoxic effects of mono- amine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells. Eur. J. Pharmacol. 434, 109–116.
   Akao Y., Maruyama W., Shimizu S., Yi H., Nakagawa Y., Shamoto- Nagai M., Youdim M. B. H., Tsujimoto Y. and Naoi M. (2002a) Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan. J. Neurochem. 82, 913–923.
   Akao Y., Maruyama W., Yi H., Shamoto-Nagai M., Youdim M. B. H. and Naoi M. (2002b) An anti-Parkinson’s disease drug, N-prop- argyl-1(R)-aminoindan (rasagiline), enhances expression of anti- apoptotic Bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci. Lett. 326, 105–108.
   Bar-Am O., Amit T. and Youdim M. B. (2004a) Contrasting neuropro- tective and neurotoxic actions of respective metabolites of anti-Par- kinson drugs rasagiline and selegiline. Neurosci. Lett. 355, 169–172.
   Bar-Am O., Yogev-Falach M., Amit T., Sagi Y. and Youdim M. B. (2004b) Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo. J. Neu- rochem. 89, 1119–1125.
   Bar-Am O., Weinreb O., Amit T. and Youdim M. B. (2005) Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. FASEB J. 19, 1899–1901. Bar-Am O., Amit T. and Youdim M. B. (2007) Aminoindan and hy- droxyaminoindan, metabolites of rasagiline and ladostigil, respec- tively, exert neuroprotective properties in vitro. J. Neurochem. 103, 500–508.
   Binda C., Hubalek F., Li M., Herzig Y., Sterling J., Edmondson D. E. and Mattevi A. (2005) Binding of rasagiline-related inhibitors to human monoamine oxidases: a kinetic and crystallographic anal- ysis. J. Med. Chem. 48, 8148–8154.
   Carlile G. W., Chalmers-Redman R. M., Tatton N. A., Pong A., Borden K. E. and Tatton W. G. (2000) Reduced apoptosis after nerve growth factor and serum withdrawal: conversion of tetrameric glyceraldehyde-3-phosphate dehydrogenase to a dimer. Mol. Pharmacol. 57, 2–12.
   Carlsson A., Adolfsson R., Aquilonius S. M., Gottfries C. G., Oreland L., Svennerholm L. and Winblad B. (1980) Biogenic amines in human brain in normal aging, senile dementia, and chronic alco- holism. Adv. Biochem. Psychopharmacol. 23, 295–304. Carrillo M. C., Minami C., Kitani K., Maruyama W., Ohashi K., Ya- mamoto T., Naoi M., Kanai S. and Youdim M. B. H. (2000) Enhancing effect of rasagiline on superoxide dismutase and cata- lase activities in the dopaminergic system in the rat. Life Sci. 67, 577–585.
   Chen J. J. and Swope D. M. (2005) Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease. J. Clin. Pharmacol. 45, 878–894.
   Colucci M. A., Moody C. J. and Couch G. D. (2008) Natural and syn- thetic quinones and their reduction by the quinone reductase enzyme NQO1: from synthetic organic chemistry to compounds with anticancer potential. Org. Biomol. Chem. 6, 637–656.
   Durkin J. P., Tremblay R., Chakravarthy B., Mealing G., Morley P., Small D. and Song D. (1997) Evidence that the early loss of membrane protein kinase C is a necessary step in the excitatory amino acid-induced death of primary cortical neurons. J. Neuro- chem. 68, 1400–1412.
   Ekblom J., Zhu Q. S., Chen K. and Shih J. C. (1996) Monoamine oxidase gene transcription in human cell lines: treatment with psychoactive drugs and ethanol. J. Neural Transm. 103, 681–692.
   Eliash S., Speiser Z. and Cohen S. (2001) Rasagiline and its (S) enantiomer increase survival and prevent stroke in salt-loaded stroke-prone spontaneously hypertensive rats. J. Neural Transm. 108, 909– 923.
   Eliash S., Shteter N. and Eilam R. (2005) Neuroprotective effect of rasagiline, a monoamine oxidase-B inhibitor, on spontaneous cell degeneration in a rat model. J. Neural Transm. 112, 991–1003.
   Finberg J. P. M., Tenne M. and Youdim M. B. H. (1981) Selective irreversible propargyl derivative inhibitors of monoamine oxidase (MAO) without the cheese effect, in Monoamine Oxidase Inhibi- tors – The State of the Art (Youdim M. B. H. and Peykel E. S., eds), pp. 31–41. Wiley, Chichester.
   Finberg J. P., Lamensdorf I., Commissiong J. W. and Youdim M. B. H. (1996) Pharmacology and neuroprotective properties of rasagiline. J. Neural Transm. Suppl. 48, 95–101.
   Finberg J. P., Takeshima T., Johnston J. M. and Commissiong J. W. (1998) Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor. Neuroreport 9, 703–707.
   Gubina E., Rinaudo M. S., Szallasi Z., Blumberg P. M. and Mufson R. A. (1998) Overexpression of protein kinase C isoform epsilon but not delta in human interleukin-3-dependent cells suppresses apoptosis and induces bcl-2 expression. Blood 91, 823–829.
   Huang W., Chen Y., Shohami E. and Weinstock M. (1999) Neuropro- tective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse. Eur. J. Phar- macol. 366, 127–135.
   Kim S. H., Fountoulakis M., Cairns N. and Lubec G. (2001) Protein levels of human peroxiredoxin subtypes in brains of patients with Alzheimer’s disease and Down syndrome. J. Neural Transm. Suppl. 223–235.
   Lamb H. M. and Goa K. L. (2001) Rivastigmine. A pharmacoeconomic review of its use in Alzheimer’s disease. Pharmacoeconomics 19, 303–318.
   Maher P. (2001) How protein kinase C activation protects nerve cells from oxidative stress-induced cell death. J. Neurosci. 21, 2929– 2938.
   Malorni W., Giammarioli A. M., Matarrese P., Pietrangeli P., Agostinelli E., Ciaccio A., Grassilli E. and Mondovi B. (1998) Protection against apoptosis by monoamine oxidase A inhibitors. FEBS Lett. 426, 155–159.
   Mandel S., Weinreb O., Amit T. and Youdim M. B. (2005) Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives. Brain Res. Brain Res. Rev. 48, 379–387.
   Maruyama W., Akao Y., Youdim M. B. H. and Naoi M. (2000a) Neu- rotoxins induce apoptosis in dopamine neurons: protection by N- propargylamine-1(R)- and (S)-aminoindan, rasagiline and TV1022. J. Neural Transm. Suppl., 171–186.
   Maruyama W., Yamamoto T., Kitani K., Carrillo M. C., Youdim M. B. H. and Naoi M. (2000b) Mechanism underlying anti-apoptotic activity of a ()) deprenyl-related propargylamine, rasagiline. Mech. Ageing Dev. 116, 181–191.
   Maruyama W., Youdim M. B. H. and Naoi M. (2000c) Antiapoptotic function of N-propargylamine-1(R)- and (S)-aminoindan, Rasagi- line and TV1022. Ann. N Y Acad. Sci. 939, 320–329.
   Maruyama W., Akao Y., Youdim M. B. H., Boulton A. A., Davis B. A. and Naoi M. (2001) Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumula- tion of glyceraldehyde-3 phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol. J. Neurochem. 78, 727–735.
   Maruyama W., Takahashi T., Youdim M. B. H. and Naoi M. (2002) The anti-parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. J. Neural Transm. 109, 467–481.
   MaruyamaW.,Weinstock M., YoudimM. B., NagaiM. and Naoi M. (2003) Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)- (3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinester- ase-monoamine oxidase inhibitor. Neurosci. Lett. 341, 233–236.
   Maruyama W., Nitta A., Shamoto-Nagai M., Hirata Y., Akao Y., Youdim M. B. H., Furukawa S., Nabeshima T. and Naoi M. (2004) N- propargyl-1 (R)-aminoindan, rasagiline, increases glial cell line- derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-kappaB transcription factor. Neu- rochem. Int. 44, 393–400.
   Naoi M., Maruyama W., Akao Y., Yi H. and Yamaoka Y. (2006) Involvement of type A monoamine oxidase in neurodegeneration: regulation of mitochondrial signaling leading to cell death or neuroprotection. J. Neural Transm. Suppl. 67–77.
   Olanow C. W., Hauser R. A., Jankovic J. et al. (2008) A randomized, double-blind, placebo-controlled, delayed start study to assess ra- sagiline as a disease modifying therapy in Parkinson’s disease (the ADAGIO study): rationale, design, and baseline characteristics. Mov. Disord. 23, 2194–2201.
   Olanow C. W., Rascol O., Hauser R. et al. (2009) A double-blind, de- layed-start trial of rasagiline in Parkinson’s disease. N. Engl. J. Med. 361, 1268–1278.
   Ou X. M., Lu D., Johnson C., Chen K., Youdim M. B., Rajkowska G. and Shih J. C. (2009) Glyceraldehyde-3-phosphate dehydrogenase- monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan. Neurotox. Res. 16, 148–159.
   Reynolds G. P., Elsworth J. D., Blau K., Sandler M., Lees A. J. and Stern G. M. (1978) Deprenyl is metabolized to methamphetamine and amphetamine in man. Br. J. Clin. Pharmacol. 6, 542–544.
   Ruvolo P. P., Deng X., Carr B. K. and MayW. S. (1998) A functional role for mitochondrial protein kinase Calpha in Bcl2 phosphorylation and suppression of apoptosis. J. Biol. Chem. 273, 25436–25442.
   Sagi Y., Mandel S., Amit T. and Youdim M. B. (2007) Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism. Neurobiol. Dis. 25, 35–44.
   Speiser Z., Katzir O., Rehavi M., Zabarski T. and Cohen S. (1998a) Sparing by rasagiline (TVP-1012) of cholinergic functions and behavior in the postnatal anoxia rat. Pharmacol. Biochem. Behav. 60, 387–393.
   Speiser Z., Levy R. and Cohen S. (1998b) Effects of N-propargyl-1- (R)aminoindan (rasagiline) in models of motor and cognition dis- orders. J. Neural Transm. Suppl. 52, 287–300.
   Speiser Z., Mayk A., Eliash S. and Cohen S. (1999) Studies with ra- sagiline, a MAO-B inhibitor, in experimental focal ischemia in the rat. J. Neural Transm. 106, 593–606.
   Sterling J., Veinberg A., Lerner D., Goldenberg W., Levy R., Youdim M. and Finberg J. (1998) (R)(+)-N-propargyl-1-aminoindan (rasagi- line) and derivatives: highly selective and potent inhibitors of monoamine oxidase B. J. Neural Transm. Suppl. 52, 301–305.
   Sterling J., Herzig Y., Goren T. et al. (2002) Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phen- ethylamine as potential treatment for Alzheimer’s disease. J. Med. Chem. 45, 5260–5279.
   Tazik S., Johnson S., Lu D., Johnson C., Youdim M. B., Stockmeier C. A. and Ou X. M. (2009) Comparative neuroprotective effects of rasagiline and aminoindan with selegiline on dexamethasone- induced brain cell apoptosis. Neurotox. Res. 15, 284–290.
   Tsujimoto Y. and Shimizu S. (2000) Bcl-2 family: life-or-death switch. FEBS Lett. 466, 6–10.
   Weinreb O., Bar-Am O., Amit T., Chillag-Talmor O. and Youdim M. B. H. (2004) Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members. FASEB J. 18, 1471–1473.
   Weinstock M., Bejar C., Wang R. H., Poltyrev T., Gross A., Finberg J. and Youdim M. B. H. (2000a) TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer’s disease. J. Neural Transm. 60(Suppl.), S157–S170.
   Weinstock M., Goren T. and Youdim M. B. H. (2000b) Development of a novel neuroprotective drug (TV3326) for the treatment of Alz- heimer’s disease, with cholinesterase and monoamine oxidase inhibitory activities. Drug Dev Res 50, 216–222.
   Weinstock M., Kirschbaum-Slager N., Lazarovici P., Bejar C., Youdim M. B. H. and Shoham S. (2001) Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti- Alzheimer drugs. Ann. NY Acad. Sci. 939, 148–161.
   Weinstock M., Poltyrev T., Bejar C., Sagi Y. and Youdim M. B. H. (2002) TV3326, a novel cholinesterase and MAO inhibitor for Alzheimer’s disease with co-morbidity of Parkinson’s disease and depression, in Mapping the Progress of Alzheimer’s and Parkin- son’s Disease (Mizuno Y., Fisher A. and Hanin I., eds), pp. 199– 204. Kluwer Academic/Plenum Publishers, New York.
   Weinstock M., Gorodetsky E., Poltyrev T., Gross A., Sagi Y. and You- dim M. B. H. (2003) A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia co- morbid with depression and Parkinson’s disease. Prog. Neuropsy- chopharmacol. Biol. Psychiatry 27, 555–561.
   Yi H., Maruyama W., Akao Y., Chen K., Iwasa K., Shih J., Youdim M. B. H. and Naoi M. (2005) N-propargylamine protects SH-SY5Y cells from apoptosis induced by an endogenous neurotoxin, N- methyl(R)salsolinol, through stabilization of mitochondrial membrane and induction of anti-apoptotic Bcl-2. J. Neural Transm. 113, 21–32.
   Yi H., Maruyama W., Akao Y., Takahashi T., Iwasa K., Youdim M. B. and Naoi M. (2006) N-propargylamine protects SH-SY5Y cells from apoptosis induced by an endogenous neurotoxin, N-methyl(R)salso- linol, through stabilization of mitochondrial membrane and induction of anti-apoptotic Bcl-2. J. Neural Transm. 113, 21–32.
   Yogev-Falach M., Amit T., Bar-Am O., Sagi Y., Weinstock M. and Youdim M. B. H. (2002) The involvement of mitogen-activated protein (MAP) kinase in the regulation of amyloid precursor pro- tein processing by novel cholinesterase inhibitors derived from rasagiline. FASEB J. 16, 1674–1676.
   Yogev-Falach M., Amit T., Bar-AM O. and Youdim M. B. H. (2003) The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives for MAPK-dependent amyloid pre- cursor protein processing. FASEB J. 17, 2325–2327.
   Yogev-Falach M., Bar-Am O., Amit T., Weinreb O. and Youdim M. B. (2006) A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing. FASEB J. 20, 2177–2179.
   Yoshida T., Yamada Y., Yamamoto T. and Kuroiwa Y. (1986) Metabo- lism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor in rat: relationship of metabolism to MAO-B inhibitory potency. Xenobiotica 16, 129–136.
   Youdim M. B. H. (2003) Rasagiline: an anti-Parkinson drug with neu- roprotective activity. Future Drugs 3, 737–749.
   Youdim M. B. H. and Weinstock M. (2002) Molecular basis of neuro- protective activities of rasagiline and the anti Alzheimer drug, TV3326, [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl car- bamate]. Cell. Mol. Neurobiol. 21, 555–573.
   Youdim M. B. H., Gross A. and Finberg J. P. M. (2001a) Rasagiline [N- propargyl-1R(+)-aminoindant], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br. J. Pharmacol. 132, 500– 506.
   Youdim M. B. H., Wadia A., Tatton N. A. and Weinstock M. (2001b) The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Ann. NY Acad. Sci. 939, 450–458.
   Youdim M. B., Bar Am O., Yogev-Falach M., Weinreb O., Maruyama W., Naoi M. and Amit T. (2005) Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J. Neurosci. Res. 79, 172–179.
   ZhuW., XieW., Pan T., Jankovic J., Li J., Youdim M. B. and LeW. (2008) Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration. J. Neurochem. 105, 1970–1978.
   
  

[ Ñîäåðæàíèå âûïóñêà N 1 | Âûïóñêè æóðíàëà | Ñïèñîê æóðíàëîâ ]